Compare PDEX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDEX | SGMT |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.4M | 169.4M |
| IPO Year | 1995 | 2021 |
| Metric | PDEX | SGMT |
|---|---|---|
| Price | $55.79 | $6.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $56.00 | $26.13 |
| AVG Volume (30 Days) | 87.1K | ★ 1.3M |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 345.00 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $66,593,000.00 | $2,000,000.00 |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.72 | ★ N/A |
| Revenue Growth | ★ 23.68 | N/A |
| 52 Week Low | $23.52 | $4.50 |
| 52 Week High | $68.99 | $10.46 |
| Indicator | PDEX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 47.42 |
| Support Level | $55.29 | $7.04 |
| Resistance Level | $55.62 | $7.39 |
| Average True Range (ATR) | 3.23 | 0.44 |
| MACD | -0.56 | -0.08 |
| Stochastic Oscillator | 23.81 | 21.77 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.